We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VERQUVO (Bayer Australia Ltd)
Product name
VERQUVO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
199 (255 working days)
Active ingredients
vericiguat
Registration type
NCE/NBE
Indication
VERQUVO (film-coated tablet) is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45% who are stabilised after a recent heart failure decompensation event requiring admission and/or IV diuretic therapy (see Section 5.1 Pharmacodynamic properties - Clinical trials).